ClinicalTrials.gg
RecruitingNCT07480668Updated Apr 29, 2026

Aromatherapy for Mental Health Promotion in IVF Patients

An interventional study of Lavender essential oil Inhalation and Synthetic lavender aroma inhalation in Anxiety, Stress and Depression Disorder, sponsored by Federal University of Minas Gerais. Recruiting at 1 site in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Primary conditionInfertilityRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infertility
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Infertility.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Federal University of Minas Gerais · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Infertility with a site in Brazil — 3 open to participants now, 3 under way, none of them phase 3. Infertility · Brazil.

Planned enrollment
14th of 31
120 · median 100
Started
2026
the only one that year
No phase
22 of 34
3 open now
Registered
34th of 34
by date
Lead sponsor
4 of 34
Federal University of Minas Gerais

Among the 34 studies in Infertility with a site in Brazil, this one is the 14th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2026, is one of 22 with no phase, and was the 34th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 34 studies in Infertility with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Infertility with a site in Brazil, or all of them as a file.
02

Study summary

The experience of infertility can cause significant emotional instability, especially for patients awaiting In Vitro Fertilization (IVF) treatment, generating anxiety, stress, and depressive symptoms. This study is a randomized clinical trial assessing the effectiveness of aromatherapy in improving mental health and quality of life in women undergoing infertility treatment. 120 participants will be randomized into three groups (Intervention, Placebo, and Control). The intervention involves the inhalation of true lavender essential oil (Lavandula angustifolia) for four weeks.

Read the detailed description

Infertility is a condition that affects approximately one in six people globally and is associated with high levels of psychological distress. Complementary therapies, such as aromatherapy, emerge as potential strategies to promote emotional well-being. This prospective, randomized, controlled clinical trial will be conducted at the Hospital das Clínicas da UFMG. Participants will be women on the waiting list for IVF. They will be randomized into three groups:

  1. Intervention Group: Inhalation of Lavandula angustifolia essential oil.
  2. Placebo Group: Inhalation of synthetic lavender essence.
  3. Control Group: Routine care only. The intervention consists of inhaling 5 drops of the substance using a personal nasal inhaler stick, twice daily (morning and night) for 15 minutes, over a period of 4 weeks. Efficacy will be measured using validated scales for anxiety, depression, stress (DASS-21), quality of life (FertiQoL), insomnia (ISI), Human Flourishing Scale (HFS), Duke Religiosity Index (DUREL), Visual Analogue Scale (VAS) for pain, General Health Questionnaire (GHQ-12) and a Qualitative questionnaire at baseline, immediately post-intervention (Week 4), and at follow-up (Week 8).
03

Conditions studied

  • Anxiety
  • Stress
  • Depression Disorder
  • Quality of Life
  • Aromatherapy
  • IVF
  • Complementary Therapies
  • Spirituality
  • Infertility

Browse trials for

Keywords

  • Infertility, Female
  • Aromatherapy
  • Lavender Oil
  • Complementary Therapy
  • Spirituality
  • IVF
  • Anxiety
  • Stress
  • Depression
  • In Vitro Fertilization
04

In context

Infertility Reclassified

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

This study's planned enrollment of 120 is close to the median of 133 across 1,415 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Federal University of Minas Gerais is the lead sponsor of 152 studies on the registry; 18 are open to participants now.

Compared within Infertility, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female gender, age over 18 years.
  • Diagnosis of infertility with indication for In Vitro Fertilization (IVF).
  • Patients on the waiting list at HC-UFMG.
  • Agreement not to practice other mind-body or herbal complementary therapies during the study.
  • DASS-21 screening score compatible with at least mild anxiety, stress, and/or depression.
  • No aversion to inhaling essential oil or synthetic lavender essence.

Exclusion criteria

Exclusion Criteria:

  • Severe neurological, psychiatric, or clinical disorders (e.g., schizophrenia, severe depression) that prevent participation.
  • Use of medications that could confound the primary outcome (e.g., sleep medications, anxiolytics, antidepressants, neuroleptics) in the 30 days prior to or during the study.
  • Known allergy to lavender products.
  • Pregnancy during the study period.
  • Use of essential oils in the last 90 days.
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Lavender essential oil group

    This intervention group will inhale 5 drops of true lavender essential oil (Lavandula angustifolia), administered via personal inhalers (olfactory sticks). The use of personal inhalers is a safe and widely used low-cost intervention that can be applied practically and accessibly, ensuring greater adherence to the protocol by the participants. The inhalation will be performed daily, upon waking in the morning and at night before sleeping, for four weeks.

    Other: Lavender essential oil Inhalation

  • Placebo comparator
    Synthetic lavender aroma group

    The placebo group will inhale 5 drops of a synthetic lavender aroma, also administered via personal inhalers. Inhalation will be performed daily, upon waking in the morning and at night before sleeping, for four weeks.

    Other: Synthetic lavender aroma inhalation

  • No intervention
    Control Group

    The control group will receive routine care throughout the 4 weeks.

Interventions

  • OtherLavender essential oil Inhalation

    The inhalation of lavender essential oil will be performed twice a day, preferably upon waking and before nighttime sleep. Participants will be instructed to settle into a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1cm from the nostrils, and beginning the inhalation through habitual breaths.The protocol stipulates that each inhalation session lasts 15 minutes, which can be timed on the participant's own cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to record completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to analyzing the effect of the practice on the well-being of women undergoing fertility treatment.

  • OtherSynthetic lavender aroma inhalation

    The inhalation of synthetic lavender essence will be performed twice a day, preferably upon waking and before bedtime. Participants will be instructed to find a quiet environment, lying down or sitting, to consciously perform the inhalation. The procedure consists of opening the inhaler, positioning it approximately 1 cm from the nostrils, and beginning the inhalation through habitual breaths. The protocol stipulates that each inhalation session should last 15 minutes, and the time can be timed on the participant's cell phone. After the inhalation is finished, the inhaler should be kept closed. To facilitate monitoring and ensure adherence to the protocol, participants will receive a weekly schedule to mark completed sessions and will be encouraged to keep an aromatherapy diary to record their perceptions and feelings throughout the study, providing qualitative data that will contribute to the analysis of the practice's effect on the well-being of women undergoing fertility treatment.

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Depression, Anxiety, and Stress Scale (DASS-21) Scores

    he DASS-21 is a set of three self-report scales containing 21 questions to measure emotional states of depression, anxiety, and stress. Each of the three subscales contains 7 items. Scores for each subscale range from 0 to 42 (calculated by summing the scores for the relevant items, which are scored from 0 to 3, and multiplying by 2). Higher scores indicate more severe symptoms of distress.

    Time frame: Baseline (Time 0), Week 4 (Time 1, end of Intervention) and Week 8 (Time 2, 4 weeks post-intervention)

Secondary outcomes

  1. Change from Baseline in Fertility Quality of Life (FertiQoL) Scores

    Assessed using the Fertility Quality of Life (FertiQoL) questionnaire. It evaluates the quality of life in people experiencing fertility problems. Items are scored on a 5-point Likert scale, and raw scores are transformed to a continuous scale ranging from 0 to 100. Higher scores indicate a better fertility-related quality of life.

    Time frame: Baseline (Day 0), Week 4 (End of Intervention) and Week 8 (4 weeks post-intervention)

  2. Change from Baseline in Insomnia Severity Index (ISI) Scores

    Assessed using the Insomnia Severity Index (ISI). The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point Likert scale (0-4). The total score ranges from 0 to 28. Higher scores indicate more severe insomnia.

    Time frame: Baseline (Day 0), Week 4 (End of Intervention) and Week 8 (4 weeks post-intervention)

  3. Change from Baseline in Flourishing Scale (EFH) Scores

    Assessed using the Harvard Human Flourishing Program measure. The instrument consists of 12 items scored on a scale of 0 to 10. The total score (Secure Flourish Index) ranges from 0 to 120. Higher scores indicate a higher level of psychosocial prosperity and flourishing.

    Time frame: Baseline (Day 0), Week 4 (End of Intervention) and Week 8 (4 weeks post-intervention)

  4. Change from Baseline in Duke University Religion Index (DUREL) Scores

    Measures religious involvement. It contains three subscales: organizational (1-6), non-organizational (1-6), and intrinsic religiosity (3-15). Higher scores indicate higher religiosity.

    Time frame: Baseline (Day 0), Week 4 (End of Intervention) and Week 8 (4 weeks post-intervention)

  5. Change from Baseline in Visual Analog Scale (VAS) for Pain

    A continuous scale for pain intensity ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate higher pain intensity.

    Time frame: Baseline (Day 0), Week 4 (End of Intervention) and Week 8 (4 weeks post-intervention)

  6. Change from Baseline in General Health Questionnaire (GHQ-12) Scores

    The General Health Questionnaire (GHQ-12) evaluates psychological distress and current mental health. Scores range from 0 to 36. Higher scores indicate worse psychological well-being and higher levels of distress.

    Time frame: Baseline (Time 0, Day 0), Week 4 (Time 1, End of Intervention) and Week 8 (Time 2, 4 weeks post-intervention)

  7. Change from Baseline in Qualitative questionnaire

    Qualitative questionnaire will analyze, through a qualitative approach, the effects of essential oil inhalation on the subjective well-being of infertile women.

    Time frame: Baseline (Time 0, Day 0), Week 4 (Time 1, End of Intervention) and Week 8 (Time 2, 4 weeks post-intervention)

08

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynecology - Federal University of Minas Gerais - Brazil
    Belo Horizonte, Minas Gerais 30130-100, Brazil
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 18, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07480668
Responsible party
Rubens Lene Carvalho Tavares (MD, PhD, Federal University of Minas Gerais) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Rubens L C Tavares, MD, PhD
Contact
rubens.ufmg@gmail.com
+55 31 3409-9764
Bárbara P Aquino, MSc
Contact
babiaquino.aromaterapia@gmail.com
Bárbara P Aquino, MSc
study chair · Federal University of Minas Gerais
Jhenifer K Rodrigues, PhD
principal investigator · POTENTIA - Technical, therapeutic, and human development consulting and advisory services
Rubens L C Tavares, MD, PhD
principal investigator · Federal University of Minas Gerais
Ubiratan Brum de Castro, PhD, MD
study chair · Federal University of Minas Gerais

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion